Befovacimab Biosimilar – Anti-TFPI mAb – Research Grade from ProteoGenix; catalogue PX-TA1582; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Befovacimab Biosimilar, also known as Anti-TFPI mAb, is a monoclonal antibody that has been developed as a biosimilar to the therapeutic antibody Befovacimab. This biosimilar has been designed to target the protein Tissue Factor Pathway Inhibitor (TFPI), which plays a crucial role in the regulation of blood coagulation. In this article, we will discuss the structure, activity, and potential applications of Befovacimab Biosimilar.
Befovacimab Biosimilar is a recombinant humanized monoclonal antibody, meaning that it is produced by genetically engineering human DNA into a non-human host, such as bacteria or mammalian cells. The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains. The heavy chains are made up of four constant regions (CH1, CH2, CH3, and CH4) and one variable region (VH), while the light chains consist of one constant region (CL) and one variable region (VL). The variable regions of the heavy and light chains are responsible for binding to the target protein, TFPI.
Befovacimab Biosimilar specifically targets TFPI, a protein that is involved in the regulation of blood coagulation. TFPI inhibits the activity of Factor Xa, a key enzyme in the coagulation cascade. By binding to TFPI, Befovacimab Biosimilar blocks its inhibitory activity, leading to increased levels of Factor Xa and promoting blood coagulation. This mechanism of action makes Befovacimab Biosimilar a potential therapeutic option for conditions associated with abnormal blood coagulation, such as thrombosis and hemophilia.
Befovacimab Biosimilar has the potential to be used in a variety of medical conditions where abnormal blood coagulation is a concern. One of the main applications of this biosimilar is in the treatment of thrombotic disorders, such as deep vein thrombosis and pulmonary embolism. By inhibiting TFPI, Befovacimab Biosimilar can help prevent the formation of blood clots and reduce the risk of these life-threatening conditions.
Another potential application of Befovacimab Biosimilar is in the treatment of hemophilia, a genetic disorder characterized by a deficiency in clotting factors. By promoting blood coagulation, Befovacimab Biosimilar can help control bleeding episodes in hemophilia patients. This biosimilar may also be used as a prophylactic treatment to prevent bleeding episodes in patients with severe hemophilia.
In addition to its potential therapeutic applications, Befovacimab Biosimilar can also be used as a research tool for studying the role of TFPI in various diseases. By blocking the inhibitory activity of TFPI, researchers can investigate the effects of increased Factor Xa levels on blood coagulation and other physiological processes.
In summary, Befovacimab Biosimilar is a recombinant humanized monoclonal antibody that targets the protein TFPI. By blocking the inhibitory activity of TFPI, this biosimilar promotes blood coagulation and has the potential to be used in the treatment of thrombotic disorders and hemophilia. It can also serve as a valuable research tool for studying the role of TFPI in various diseases. With its unique structure and targeted activity, Befovacimab Biosimilar holds promise as a potential therapeutic option for conditions associated with abnormal blood coagulation.
ProteoGenix catalogue number PX-TA1582. For research use only.
Target: Befovacimab Biosimilar – Anti-TFPI mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: WB, ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Befovacimab Biosimilar – Anti-TFPI mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
